Add like
Add dislike
Add to saved papers

Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with 177 Lu.

PURPOSE: To compare the effectiveness of trastuzumab-modified gold nanoparticles (AuNP) labeled with 177 Lu (trastuzumab-AuNP-177 Lu) targeted to HER2 with non-targeted AuNP-177 Lu for killing HER2-overexpressing breast cancer (BC) cells in vitro and inhibiting tumor growth in vivo following intratumoral (i.t.) injection.

METHODS: AuNP (30 nm) were modified with polyethylene glycol (PEG) polymers linked to trastuzumab or to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelators to complex 177 Lu. The binding and internalization of trastuzumab-AuNP-177 Lu in HER2-positive SK-BR-3, BT-474 and MDA-MB-361 human BC cells were studied. Clonogenic survival and DNA double-strand breaks (DSBs) were measured after exposure of SK-BR-3 or MDA-MB-361 cells to trastuzumab-AuNP-177 Lu or AuNP-177 Lu. NOD/SCID mice with s.c. MDA-MB-361 tumor xenografts were treated by i.t. injection of 3 MBq (0.15 mg) of trastuzumab-AuNP-177 Lu, AuNP-177 Lu or normal saline. Tumor growth was measured over 16 days and normal tissue toxicity evaluated.

RESULTS: Trastuzumab-AuNP-177 Lu was bound and internalized by HER2 positive BC cells (KD  = 7.6 ± 2.0 nM). Trastuzumab-AuNP-177 Lu was 42.9 and 2.6-fold more effective than AuNP-177 Lu at decreasing the clonogenic survival of SK-BR-3 (1.3 × 106 HER2/cell) and MDA-MB-361 (5.1 × 105 HER2/cell) cells, respectively, exposed overnight to these agents (1.5 nM; 20 MBq/mg Au). Under the same treatment conditions, 10-fold and 2.8-fold more DNA DSBs were observed in SK-BR-3 and MDA-MB-361 cells, respectively, exposed to trastuzumab-AuNP-177 Lu than AuNP-177 Lu. Trastuzumab-AuNP-177 Lu was 1.8-fold more effective at inhibiting tumor growth than AuNP-177 Lu. No or minimal normal tissue toxicity was observed for trastuzumab-AuNP-177 Lu or AuNP-177 Lu treatments.

CONCLUSION: Trastuzumab-AuNP-177 Lu enables an efficient local radiation treatment of HER2-positive BC.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app